Tris Pharma
US Highway 130
Monmouth Junction
NJ
08852
United States
Tel: (732) 940-2800
Website: https://www.trispharma.com/
About Tris Pharma
Founded in 2000, Tris Pharma, Inc. (www.trispharma.com) is the 3rd largest specialty pharmaceutical company in the United States. With our intense focus on the application of physical chemistry in biological systems, coupled with the requirements of manufacturing and market demands, we have grown our employee base over 250% in the past three years. Specifically, we are engaged in research, development, and manufacturing of both OTC and Rx branded products and specialty generic products. Our mission is to understand the science driving the delivery of drugs into the human body;develop and bring to market products that add value to our customers and patients and provide a benefit to our company, employees and society at large.
70 articles with Tris Pharma
-
Tris Pharma Announces Hiring of New Vice President of Quality & Compliance
8/27/2018
Tris Pharma, Inc. today announced the joining of Jeffery Palmer as its new Vice President and Head of Quality & Compliance.
-
Tris Pharma, Inc. Appoints New Chief Commercial Officer For Brand Business
3/10/2017
-
Tris Pharma, Inc.’s Results From A Laboratory Classroom Study Of DYANAVEL XR In Children With ADHD Featured At APSARD
2/9/2017
-
Tris Pharma, Inc. Release: FDA Accepts CCP-08 NDA For Full Review
12/21/2016
-
Tris Pharma, Inc. Announces The Launch Of DYANAVEL XR (Amphetamine) Extended-Release Oral Suspension, CII For The Treatment Of Children With ADHD
4/19/2016
-
Tris Pharma, Inc. Announces Appointment Of Chief Commercial Officer Of Its New Brand Business
4/7/2016
-
Tris Pharma, Inc. Announces First Ever FDA-Approved Extended-Release Chewable Tablet
12/16/2015
-
Tris Pharma, Inc. Receives FDA Approval Of Dyanavel XR (amphetamine) CII As Once-Daily Liquid For Treatment Of ADHD In Children
10/20/2015
-
Tris Pharma, Inc. Launches Generic Tussionex As Par's Rights Expire
10/1/2015
-
Tris Pharma, Inc. And Pfizer Consumer Healthcare Enter Into Agreement To Commercialize 12-Hour Extended Release Dextromethorphan Cough Syrup Under The Robitussin Brand
6/29/2015
-
Tris Pharma, Inc. Announces The FDA Acceptance Of NDA For Dyanavel XR
5/21/2015
-
Vernalis PLC And Tris Pharma, Inc. Receive FDA Approval Of NDA For Tuzistra XR (Codeine Polistirex And Chlorpheniramine Polistirex)
5/1/2015
-
Tris Pharma, Inc. Selected As An Award Winner In The New Jersey Business & Industry Association's 2014 Awards For Excellence
8/27/2014
-
Vernalis PLC And Tris Pharma, Inc. Release: Submission Of Tuzistra XR (CCP-01) NDA To FDA
6/30/2014
-
Tris Pharma, Inc. Expands R&D Team With Addition Of Chief Medical Officer And Vice President Of Regulatory Affairs
6/26/2014
-
Tris Pharma, Inc. Announces Management Changes
4/1/2014
-
Tris Pharma, Inc. and FSC Laboratories Sign Definitive Commercialization Agreement for Karbinal™ ER (carbinoxamine maleate) Extended-Release Oral Suspension
9/4/2013
-
Tris Pharma, Inc.'s Generic Pharmaceuticals Business Launches Dextroamphetamine Sulfate Oral Solution
7/10/2013
-
Tris Pharma, Inc. Hires President for Generic Pharmaceuticals Business
6/20/2013
-
Tris Pharma, Inc.'s Ketan Mehta Among Ernst & Young LLP Entrepreneur of the Year® 2013 Finalists in New Jersey
5/2/2013